Home / Stocks / VRTX

Vertex Pharmaceuticals (VRTX, Biotechnology) Stock Valuation & Fair Value Poor on forward returns

Vertex Pharmaceuticals (VRTX, Biotechnology) trades at a blended P/E of 27.0, about 58% below its historical normal valuation, with a forward growth estimate of 15.3% and a PEG of 1.76. Analysts' one-year estimates have been hit 36% of the time. Priced at its historical normal P/E of 64.0 on the same blended earnings, the 2026-10-02 close of $504.73 corresponds to about $1,200 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-10-05
Blended P/E
27.0
Normal P/E
64.0
PEG
1.76
Fwd growth
15.3%
Div yield
0.0%
RSI (14)
38.9
Neutral
Technical context
  • Price $503.25 at the 2026-10-08 close, 2.1% below the 20-day average ($514.08) and 3.2% below the 50-day ($519.90).
  • RSI (14) at 38.9.
  • 52-week range $407.37 to $557.96: the price is 9.8% below the high and 23.5% above the low.

The Street vs SeerForecast

Wall Street's mean price target for VRTX is $571.39 across 28 analysts, 13.5% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: poor on forward returns. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from weak on forward returns (2026-06-03) to poor on forward returns (2026-10-05).

Blended P/E and rating by weekBlended P/E moved from 24.0 to 27.0 between 2026-06-03 and 2026-10-02, against a normal P/E of 64.0, with 3 rating changes over 37 recorded weeks.2026-06-03: P/E 24.0, Weak on forward returns, recalculated for the week of 2026-06-032026-06-10: P/E 23.9, Weak on forward returns, recalculated for the week of 2026-06-102026-06-12: P/E 23.9, Weak on forward returns, recalculated for the week of 2026-06-142026-06-16: P/E 23.9, Weak on forward returns, recalculated for the week of 2026-06-162026-06-18: P/E 23.9, Weak on forward returns, recalculated for the week of 2026-06-212026-07-02: P/E 26.6, Poor on forward returns, recalculated for the week of 2026-07-022026-07-06: P/E 28.2, Poor on forward returns, recalculated for the week of 2026-07-062026-07-09: P/E 28.2, Poor on forward returns, recalculated for the week of 2026-07-092026-07-10: P/E 25.9, Weak on forward returns, recalculated for the week of 2026-07-122026-07-13: P/E 25.9, Weak on forward returns, recalculated for the week of 2026-07-132026-07-14: P/E 25.9, Weak on forward returns, recalculated for the week of 2026-07-142026-07-20: P/E 25.9, Weak on forward returns, recalculated for the week of 2026-07-202026-07-22: P/E 25.9, Weak on forward returns, recalculated for the week of 2026-07-222026-07-24: P/E 25.4, Weak on forward returns, recalculated for the week of 2026-07-252026-07-27: P/E 25.4, Weak on forward returns, recalculated for the week of 2026-07-272026-07-31: P/E 25.6, Weak on forward returns, recalculated for the week of 2026-07-312026-07-31: P/E 25.4, Weak on forward returns, recorded live 2026-08-032026-08-07: P/E 25.9, Weak on forward returns, recalculated for the week of 2026-08-072026-08-07: P/E 26.5, Poor on forward returns, recorded live 2026-08-102026-08-14: P/E 27.6, Poor on forward returns, recalculated for the week of 2026-08-142026-08-14: P/E 27.1, Poor on forward returns, recorded live 2026-08-172026-08-21: P/E 28.9, Poor on forward returns, recalculated for the week of 2026-08-212026-08-21: P/E 29.3, Poor on forward returns, recorded live 2026-08-242026-08-27: P/E 29.3, Poor on forward returns, recalculated for the week of 2026-08-272026-08-28: P/E 29.3, Poor on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 29.0, Poor on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 29.0, Poor on forward returns, recorded live 2026-08-312026-09-04: P/E 29.2, Poor on forward returns, recalculated for the week of 2026-09-052026-09-04: P/E 29.2, Poor on forward returns, recorded live 2026-09-072026-09-11: P/E 27.6, Poor on forward returns, recalculated for the week of 2026-09-122026-09-11: P/E 27.6, Poor on forward returns, recorded live 2026-09-142026-09-18: P/E 27.2, Poor on forward returns, recalculated for the week of 2026-09-192026-09-18: P/E 27.2, Poor on forward returns, recorded live 2026-09-212026-09-25: P/E 28.1, Poor on forward returns, recalculated for the week of 2026-09-262026-09-25: P/E 28.1, Poor on forward returns, recorded live 2026-09-282026-10-02: P/E 27.0, Poor on forward returns, recalculated for the week of 2026-10-032026-10-02: P/E 27.0, Poor on forward returns, recorded live 2026-10-0540.060.0Jun 3Jul 3Aug 2Sep 2Oct 2Normal P/E 64.0
Weak on forward returnsPoor on forward returnsLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 24.0-63%Weak on forward returns (recalculated)
2026-06-10P/E 23.9-63%Weak on forward returns (recalculated)
2026-07-02P/E 26.6-58%Poor on forward returns (recalculated)
2026-07-12P/E 25.9-60%Weak on forward returns (recalculated)
2026-08-10P/E 26.5-59%Poor on forward returns
2026-08-24P/E 29.3-54%Poor on forward returns
2026-10-05P/E 27.0-58%Poor on forward returns ← now
Show all 37 weeks
WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 24.0-63%Weak on forward returns (recalculated)
2026-06-10P/E 23.9-63%Weak on forward returns (recalculated)
2026-06-14P/E 23.9-63%Weak on forward returns (recalculated)
2026-06-16P/E 23.9-63%Weak on forward returns (recalculated)
2026-06-21P/E 23.9-63%Weak on forward returns (recalculated)
2026-07-02P/E 26.6-58%Poor on forward returns (recalculated)
2026-07-06P/E 28.2-56%Poor on forward returns (recalculated)
2026-07-09P/E 28.2-56%Poor on forward returns (recalculated)
2026-07-12P/E 25.9-60%Weak on forward returns (recalculated)
2026-07-13P/E 25.9-60%Weak on forward returns (recalculated)
2026-07-14P/E 25.9-60%Weak on forward returns (recalculated)
2026-07-20P/E 25.9-60%Weak on forward returns (recalculated)
2026-07-22P/E 25.9-60%Weak on forward returns (recalculated)
2026-07-25P/E 25.4-60%Weak on forward returns (recalculated)
2026-07-27P/E 25.4-60%Weak on forward returns (recalculated)
2026-07-31P/E 25.6-60%Weak on forward returns (recalculated)
2026-08-03P/E 25.4-60%Weak on forward returns
2026-08-07P/E 25.9-60%Weak on forward returns (recalculated)
2026-08-10P/E 26.5-59%Poor on forward returns
2026-08-14P/E 27.6-57%Poor on forward returns (recalculated)
2026-08-17P/E 27.1-58%Poor on forward returns
2026-08-21P/E 28.9-55%Poor on forward returns (recalculated)
2026-08-24P/E 29.3-54%Poor on forward returns
2026-08-27P/E 29.3-54%Poor on forward returns (recalculated)
2026-08-28P/E 29.3-54%Poor on forward returns (recalculated)
2026-08-30P/E 29.0-55%Poor on forward returns (recalculated)
2026-08-31P/E 29.0-55%Poor on forward returns
2026-09-05P/E 29.2-54%Poor on forward returns (recalculated)
2026-09-07P/E 29.2-54%Poor on forward returns
2026-09-12P/E 27.6-57%Poor on forward returns (recalculated)
2026-09-14P/E 27.6-57%Poor on forward returns
2026-09-19P/E 27.2-58%Poor on forward returns (recalculated)
2026-09-21P/E 27.2-58%Poor on forward returns
2026-09-26P/E 28.1-56%Poor on forward returns (recalculated)
2026-09-28P/E 28.1-56%Poor on forward returns
2026-10-03P/E 27.0-58%Poor on forward returns (recalculated)
2026-10-05P/E 27.0-58%Poor on forward returns ← now

Frequently asked questions

Is Vertex Pharmaceuticals stock overvalued?

At a blended P/E of 27.0 versus its historical normal P/E of 64.0, Vertex Pharmaceuticals trades about 58% below its typical valuation, with a PEG of 1.76 on 15.3% forward growth. tickerseer currently rates it poor on forward returns.

What is Vertex Pharmaceuticals's fair value and PEG?

Vertex Pharmaceuticals trades at a blended P/E of 27.0 against a historical normal P/E of 64.0, a PEG of 1.76, and a forward growth estimate of 15.3%. Priced at its historical normal P/E of 64.0 on the same blended earnings, the 2026-10-02 close of $504.73 corresponds to about $1,200 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Vertex Pharmaceuticals changed?

tickerseer's rating moved from weak on forward returns (2026-06-03) to poor on forward returns (2026-10-05).

What is the analyst price target for Vertex Pharmaceuticals?

The mean Wall Street price target for Vertex Pharmaceuticals is $571.39 across 28 analysts, 13.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track VRTX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.